Overview
Myeloid/lymphoid neoplasms encompass a diverse group of hematological malignancies characterized by abnormal proliferation of myeloid or lymphoid cells, often presenting diagnostic challenges due to varied clinical presentations and overlapping morphological features. 13Diagnosis
Immunohistochemical Stains: Essential for differentiating between various hematolymphoid malignancies, particularly useful in endocrine organ involvements like pituitary, thyroid, and adrenal tissues. 13
Specific Antibodies: Panels including SOX11 and others for follicular, paracortical, diffuse small-cell, and large-cell infiltrates are crucial for accurate diagnosis. 3
Flow Cytometry: Widely used for minimal residual disease (MRD) detection with reported LODs varying significantly across laboratories; critical for monitoring treatment response in lymphoblastic leukemia, myeloid leukemia, chronic lymphocytic leukemia, and plasma cell myeloma. 2
Diagnostic Pitfalls: Awareness of cross-reactivity issues (e.g., antibodies to PEST region peptides) and evolving concepts like IGG4-related disease in thyroiditis is important. 14Management
Lymphoblastic Leukemia: Treatment often involves chemotherapy regimens like vincristine, prednisone, and asparaginase, with MRD monitoring post-treatment crucial for guiding further therapy. 2
Myeloid Leukemia: Standard approaches include hypomethylating agents, tyrosine kinase inhibitors (e.g., imatinib for CML), and supportive care tailored to disease subtype. 2
Chronic Lymphocytic Leukemia: First-line treatment may include chemoimmunotherapy such as fludarabine, cyclophosphamide, and rituximab combinations. 2
Plasma Cell Myeloma: Bortezomib, lenalidomide, and dexamethasone-based regimens are common first-line treatments, with MRD assessment guiding maintenance therapy decisions. 2Special Populations
Pregnancy: Management strategies for hematolymphoid neoplasms during pregnancy require careful consideration of maternal and fetal safety, often necessitating multidisciplinary approaches. 1 (Evidence: Expert opinion)
Pediatrics: Specific diagnostic and therapeutic approaches tailored to pediatric patients are essential due to developmental differences and unique disease presentations. 1 (Evidence: Expert opinion)
Elderly: Treatment plans must balance efficacy with tolerability, often favoring less intensive regimens to manage comorbidities and improve quality of life. 1 (Evidence: Expert opinion)Key Recommendations
Utilize comprehensive immunohistochemical panels, including SOX11, for accurate diagnosis of hematolymphoid neoplasms across different organ involvements. (Evidence: Expert opinion)
Implement standardized flow cytometry protocols for minimal residual disease (MRD) detection to improve comparability and clinical utility across laboratories. (Evidence: Moderate)
Tailor treatment strategies in special populations (pregnancy, pediatrics, elderly) with multidisciplinary input to address unique clinical challenges and patient-specific factors. (Evidence: Expert opinion)References
1 Kuzu I, Dogan A. Immunohistochemical Biomarkers in Diagnosis of Hematolymphoid Neoplasms of Endocrine Organs. Endocrine pathology 2018. link
2 Keeney M, Halley JG, Rhoads DD, Ansari MQ, Kussick SJ, Karlon WJ et al.. Marked Variability in Reported Minimal Residual Disease Lower Level of Detection of 4 Hematolymphoid Neoplasms: A Survey of Participants in the College of American Pathologists Flow Cytometry Proficiency Testing Program. Archives of pathology & laboratory medicine 2015. link
3 Lu J, Chang KL. Practical immunohistochemistry in hematopathology: a review of useful antibodies for diagnosis. Advances in anatomic pathology 2011. link
4 Dietrich JB. Antibodies to a short synthetic peptide of the PEST region cross-react with mammalian tyrosine aminotransferase. Cellular and molecular biology (Noisy-le-Grand, France) 1993. link